SELECTBIO Conferences Cancer Immunotherapy & Biofluid Biopsies 2016

Cancer Immunotherapy & Biofluid Biopsies 2016
Venue: Boston, Massachusetts USA
Date: 1 - 2 November, 2016


Keynote Speakers

Christine Biron

Christine Biron
Esther Elizabeth Brintzenhoff Professor of Medical Science, Professor of Molecular Microbiology and Immunology, Brown University

Shana Kelley

Shana Kelley
Professor, University of Toronto

Ellen Beasley

Ellen Beasley
Senior Vice President, Products and Services R&D, Genomic Health

Cloud Paweletz

Cloud Paweletz
Head of the Translational Research Laboratory, Dana Farber Cancer Institute

E Antonio Chiocca

E Antonio Chiocca
Harvey Cushing Professor of Neurosurgery and Chairman, Department of Neurosurgery, Brigham and Women's Hospital/Harvard Medical School

Tony Godfrey

Tony Godfrey
Associate Chair of Research, Department of Surgery, Boston University Medical Center

Paul Song

Paul Song
Chief Medical Officer, Cynvenio Biosystems

Fred Kramer

Fred Kramer
Professor of Microbiology, Biochemistry & Molecular Genetics, New Jersey Medical School Rutgers University

Gordon Freeman

Gordon Freeman
Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Michael King

Michael King
Managing Director and Senior Biotechnology Analyst, JMP Securities

AmirAli Talasaz

AmirAli Talasaz
Co-Founder, President & COO, Guardant Health

Gary S Stein

Gary S Stein
Professor and Chairperson, Department of Biochemistry, Director, University of Vermont Cancer Center

David Hafler

David Hafler
William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, Yale University

Overview

Cancer Immunotherapy represents a portfolio of approaches aimed at deploying the immune system against tumor targets in vivo.  There is a growing body of scientific and clinical evidence that these approaches are yielding clinically-actionable strategies for cancer treatment.

Biofluid Biopsies represents the harvest of circulating biomarkers to monitor progression of disease especially in cancer.  The minimally-invasive means of capture of circulating-free DNA (cfDNA), circulating tumor cells (CTCs), circulating proteins and circulating extracellular vesicles (EVs) represents a new paradigm for longitudinal monitoring of disease and therapy progression.

Cancer Immunotherapy & Biofluid Biopsies 2016 brings together the key opinion leaders in the immunotherapy and tumor immunology fields to address the most up-to-date strategies for immune therapy and means by which immunotherapies may be rationally-combined with more traditional anti-cancer therapeutics.  This field is converging with biofluid biopsies/liquid biopsies and therefore this conference brings together these two disciplines as they are co-evolving.

This conference also addresses biomarkers and companion diagnostics (CDx) which can be utilized to "target patient populations" suitable for immunotherapies.

Presentations from researchers and clinician-scientists at this conference discuss the most recent themes and clinical data.

Call for Posters

You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!

Poster Submission Deadline: 17 October 2016

Agenda Topics

  • Biomarkers & Companion Diagnostics for Immunotherapy
  • Checkpoint and Non-Checkpoint Immunotherapies
  • Chimeric Antigen Receptor (CAR) T-Cells in Cancer Immunotherapy
    • CAR T-Cell Design
  • Circulating Biomarkers for Monitoring Disease Progression and Treatment Outcomes
    • Circulating Cell-Free DNA (cfDNA)
    • Circulating Tumor Cells (CTCs)
    • Extracellular Vesicles (EVs): Exosomes and Microvesicles as Circulating Biomarker Carriers
  • Combination Cancer Immunotherapy
  • Costimulatory Molecules for Immunological Activation & Therapeutic Intervention
    • CD28 and others
  • Immunomodulatory Antibodies
  • Liquid Biopsies for Minimally-Invasive Diagnostics
  • Natural Killer (NK) Cells in Cancer Immunotherapy
  • New and Emerging Targets for Immunological Intervention in Cancer
    • PD-1/PDL-1
  • Oncolytic Viruses as Cancer Immunotherapeutics
  • Peptide Vaccines
  • Preclinical Animal Models for Immuno-Oncology
  • Small Molecules in Cancer Immune Therapy
    • Clinical Results
    • Mechanisms of Action
  • Targeting Signaling Pathways in Cancer as Therapeutic Intervention
  • Targeting the Tumor Microenvironment

Confirmed Speakers to date

Leonora Balaj, Instructor in Neurology, Mass General Hospital (MGH)/Harvard Medical School
Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute
Brian Dougherty, Director, Translational Genomics, AstraZeneca Oncology
Galina Gabriely, Instructor, Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital
Carmen Gerlach, Researcher, Harvard Medical School
Tony Godfrey, Associate Chair - Research, Department of Surgery, Boston University Medical Center
Malini Harigopal, Associate Professor, Dept of Pathology, Breast and Cytopathology, Yale University
Nikhil Joshi, Assistant Professor of Immunobiology, Yale University
Stephen Kirk, Non-Clinical Immunotoxicologist, Covance Laboratories Ltd
Thomas-Oliver Kleen, Executive VP Immune Monitoring, Epiontis GmbH
Francesco Marangoni, Instructor in Medicine, Massachusetts General Hospital/Harvard Medical School
Oscar Puig, Senior Vice President, Research & Development, Recombine
Johan Skog, Chief Scientific Officer, Exosome Diagnostics Inc


Exhibition Sponsors Media Sponsors Official Journal Partner Networking
Drug Discovery WoMetaTagsrld U-Networks
Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean

Industry Event Calendar
Search for Pharmaceuticals

Related Events
Molecular Med Tri-Con